Navigation Links
Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials
Date:3/20/2008

Wows Rome audience with live study setup and launch...

WAYLAND, Mass., March 20 /PRNewswire/ -- Tourtellotte Solutions, a global leader in bio-pharmaceutical clinical trials software, announces the launch of its Trident IWR(TM) next-generation IWR/IVRS platform for phase II-IV studies. Trident's unique parameter driven + custom pluggable design leaps ahead of legacy IVRS technologies and promises to deliver a new era of needed scalability, productivity, and ease-of-use to the straining global clinical IVRS market.

Tourtellotte representatives demonstrated the next-generation Trident IWR, fully integrated with the tcVisualize(TM) clinical supply simulator, to an appreciative audience at the VIB Clinical Supply Europe conference in Rome, Italy on February 25th, 2008.

Clinical IVRS (or IWR) systems are the source and driver of patient randomization, drug dispensing, and trial supply logistics, and as such are critical to the multi-center clinical trials that they support. Having grown up from older telephony-based technology and designs, however, current IVRS platforms are difficult to scale, and time consuming to set up. Some estimates put the industry standard programming time for a new clinical trial in IVRS to be 8-12 weeks, with commensurate cost, risk and technical design and validation overhead.

A parameter driven IWR such as Trident can eliminate this lead-time and a host of other difficulties due to its parameterized design, coupled with automatic 2-way integration with trial simulators such as tcVisualize. The Tourtellotte team in Rome demonstrated this concept by soliciting a live study design from the audience, then setting up and simulating the study in tcVisualize, and exporting the study to Trident. After switching on the study in Trident IWR, the TS team then acted as a clinical site to screen, randomize, and dose subjects, and then brought the data back into tcVisualize to show end to end study design, launch,
'/>"/>

SOURCE Tourtellotte Solutions
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Discovery Institute Bioethicist Lauds Breakthrough in Stem Cells Research that Eliminates Need for Human Cloning
2. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
3. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
4. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
5. Diamyd Gets Authorization to Begin Phase III Study in the US
6. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
7. Study Finds Broadband Access Key to Empowerment of Minority Communities
8. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
9. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
10. Fralex reaches 100th patient milestone in fibromyalgia study
11. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Potential Blockbuster Product for High Risk Cardiovascular ... ... Calif., Jan. 7 ,Genzyme Corp. (Nasdaq: GENZ ) and Isis ... a major strategic alliance in which,Genzyme will develop and commercialize mipomersen, ...
... Jan. 7 Cephalon, Inc. (Nasdaq:,CEPH) announced today that ... at the JPMorgan Healthcare Conference are now available on ... . On Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., ... at the,Conference beginning at 2:00 p.m. Pacific Time (5 ...
... of Investment Success -, GAITHERSBURG, Md., Jan. ... of AstraZeneca plc (LSE: AZN.L, NYSE:,AZN), today announced ... will broaden its focus to include areas of ... areas of,cardiovascular and metabolic disease, pain and central ...
Cached Biology Technology:Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3
(Date:12/17/2014)... 2014 The Defense Logistics Agency is insourcing its ... counterfeit microcircuits from entering into its supply chain. ... anti-counterfeit initiative dubbed DNA marking. The capability will validate ... throughout the supply chain. The new quality control measures ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... in the most exciting and unsettling period in the ... in public. On the one hand, the ... the psychiatric diagnostic manual, DSM-V, representing the current best ... categorize the enormously complex pattern of human emotional, cognitive, ...
... University of Adelaide has shown for the first time ... greatly increasing the risk of complications for themselves and their unborn ... world, researchers from the University,s Robinson Institute compared data ... results have been published online ahead of print in the ...
... time that the blood vessels that transport blood to and ... just bodily pipelines. Arterioles and capillaries, the small vessels, actually ... blood they,re carrying. Biomedical engineers at Drexel University, who study ... how they do it. The team, which includes Drs. ...
Cached Biology News:What is the brain telling us about the diagnoses of schizophrenia and bipolar disorder? 2Smoking + asthma + pregnant = a dangerous combination 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
Request Info...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
...
Request Info...
Biology Products: